A5100661293- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Cancer-related molecular mechanisms research
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Liver Disease Diagnosis and Treatment
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Liver Disease and Transplantation
- MicroRNA in disease regulation
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
Shanghai Pulmonary Hospital
2016-2025
Tongji University
2016-2025
First Hospital of Shanxi Medical University
2018-2025
Shanxi Medical University
2018-2025
Children's Hospital of Philadelphia
2022-2025
Third Hospital of Nanchang
2025
Nanchang University
2025
Fujian Agriculture and Forestry University
2024
Lishui Central Hospital
2024
Wenzhou Medical University
2024
Abstract The lack of response to treatment in most lung cancer patients suggests the value broadening benefit anti–PD-1/PD-L1 monotherapy. Judicious dosing antiangiogenic agents such as apatinib (VEGFR2-TKI) can modulate tumor immunosuppressive microenvironment, which contributes resistance treatment. We therefore hypothesized that inhibiting angiogenesis could enhance therapeutic efficacy PD-1/PD-L1 blockade. Here, using a syngeneic mouse model, we demonstrated low-dose alleviated hypoxia,...
// Ningning Cheng 1,* , Weijing Cai Shengxiang Ren 1 Xuefei Li 2 Qi Wang Hui Pan Mingchuan Zhao Jiayu Yishi Zhang Chao Xiaoxia Chen Ke Fei 3 Caicun Zhou and Fred R. Hirsch 4 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, University School Cancer Institute, Shanghai, P. China Lung Immunology, Thoracic Surgery, Pathology, Colorado Center, Aurora, Colorado, USA * These authors have contributed equally to this work Correspondence to: Zhou, email: Keywords : UCA1,...
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐1/PD‐L1) pathway have profoundly improved clinical management of non‐small‐cell lung cancer (NSCLC). Nevertheless, superiority single‐agent PD‐1/PD‐L1 in pretreated EGFR mutant patients has turned out to be moderate. One proposed mechanism for poor response immune is an immunosuppressive tumor microenvironment. Therefore, we utilized two autochthonous ‐driven models investigate dynamic microenvironmental...
CD73 is one of the critical component in formation immunosuppressive microenvironment cancers. We aimed to provide an overview current status expression and its relationship with clinicopathlogical features prognosis different cancers.PubMed, Web Science, EMBASE Cochrane library were searched identify relevant studies. level distinct cancers characteristics investigated using online database. Meta-analyses conducted RevMan v5.0 STATA v12.0.Fourteen publications 2951 cases included. The...
Purpose Genetic intratumoral heterogeneity has a profound influence on the selection of clinical treatment strategies and addressing resistance to targeted therapy. The purpose this study was explore potential effect both genetic pathologic characteristics ALK-rearranged lung adenocarcinoma (LADC). Methods We tested ALK fusions EGFR mutations in 629 patients with LADC by using laser-capture microdissection capture spatially separated tumor cell subpopulations various subtypes test for...
Our previous study demonstrated that long non-coding RNA (lncRNA) BC087858 could stimulate acquired resistance to EGFR-TKIs in non-small cell lung (NSCLC) but the specific regulatory mechanism remained unknown. We aimed explore role and of lncRNA on resistance. LncRNA mRNA expression was detected by reverse transcription polymerase chain reaction different NSCLC lines tissues. The relationship between clinicopathological factors performed Cox multivariate regression analysis....
To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, immune infiltrates. Whole-exome sequencing was performed on 189 surgically resected LUSC. TMB defined as sum nonsynonymous single nucleotide indel variants. CD8+ tumor-infiltrating lymphocyte (TIL) density expression were evaluated by immunohistochemistry. Six infiltrates estimated using an online database. The median...
Immunotherapy for malignant tumors has made great progress, but many patients do not benefit from it. The complex intratumoral heterogeneity (ITH) hindered the in-depth exploration of immunotherapy. Conventional bulk sequencing masked intratumor complexity, preventing a more detailed discovery impact ITH on treatment efficacy. Hence, we initiated this study to explore at multi-omics spatial level and seek prognostic biomarkers immunotherapy efficacy considering presence ITH.
KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, response to immunotherapy heterogeneous owing distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenocarcinoma displays poor PD-1 blockade whereas mechanism remains undetermined.
BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of patients with advanced non–small cell lung cancer (NSCLC) who have EGFR mutations. Recent studies indicated that some positive mutations were refractory to TKIs if they harbored a B‐cell chronic lymphocytic leukemia/lymphoma (Bcl‐2)‐like 11 ( Bim ) deletion polymorphism. The objective current work was retrospectively study polymorphism in Chinese NSCLC and its correlation...
The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer. present study aimed to investigate correlation long non-coding RNA (lncRNA) H19 with cisplatin-resistance and clinical outcome adenocarcinoma. In our study, expression cisplatin-resistant A549/DDP cells was unregulated. Knockdown restored response cisplatin. H19-mediated chemosensitivity enhancement associated metastasis, induction G0/G1 cell-cycle arrest, cell...
It is important to analyze and track Epidermal Growth Factor Receptor (EGFR) mutation status for predicting efficacy monitoring resistance throughout EGFR-tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) patients. The objective of this study was determine the feasibility predictive utility EGFR detection peripheral blood.Plasma, serum tumor tissue samples from 164 NSCLC patients were assessed mutations using Amplification Refractory Mutation System...
Abstract Background Although oncogenic driver mutations were thought to be mutually exclusive in non‐small cell lung cancer (NSCLC), certain tumors harbor co‐occurring and represent a rare molecular subtype. The evaluation of the clinical features therapeutic response associated with this NSCLC subtype will vital for understanding heterogeneity treatment improving management these patients. Methods This retrospective study included 3774 samples from patients diagnosed NSCLC. All screened...
Background Immune checkpoint inhibitors (ICIs) brought about a major paradigm shift in non-small cell lung cancer (NSCLC) treatment. However, the use of ICIs is related to an unforeseeable pattern immune-related adverse events (irAEs). Hence, more precise biomarkers are needed predict incidence irAEs prevent overtreatment and decrease occurrences irAEs. This study was designed identify capable clinical features plasma inflammatory factors for predicting Methods A total 67 patients who...
Abstract Cuproptosis is a newly discovered form of cell death. It regulated by string genes. The genes are identified to influence the tumor progression, but in glioma, cuproptosis-related little studied. Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) were used screen for SLC31A1 gene expression glioma healthy tissue samples. results validated using Gene Omnibus (GEO) quantitative real-time polymerase chain reaction (qPCR). Human Protein (HPA) National Institute’s Clinical...